Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1635 views | HTML 1930 views | ?
Di Wu1,*, Chongyang Duan2,*, Fenfang Wu1, Liyong Chen3 and Size Chen1
1 Central Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
2 Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China
3 Guangdong Province Key Laboratory for Medical Molecular Diagnostics, China-America Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China
* These authors have equally contributed to this work
Size Chen, email:
Liyong Chen, email:
Keywords: immune checkpoint inhibitor, tyrosine kinase inhibitor, chemotherapy, wild-type epidermal growth factor receptor, lung cancer
Received: April 15, 2017 Accepted: July 26, 2017 Published: August 16, 2017
Background: The recommendations regarding the optimum treatment for advanced non-small-cell lung cancer (NSCLC) patients with wild-type (WT) epidermal growth factor receptor (EGFR) tumors remain unclear. This meta-analysis was conducted to assess the efficacy among programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) antibody, EGFR-tyrosine kinase inhibitors (TKI) and chemotherapy in second-and third-line therapy.
Patients and methods: Randomized trials investigating two of the three treatments were searched and included. Multiple treatments comparison and pairwise comparison were performed to assess overall survival (OS) and progression-free survival (PFS), expressed as hazard ratios (HRs). The effect of prespecified study-level characteristics was assessed by subgroup analysis and meta-regression.
Results: 12 randomized trials accruing 3341 advanced patients with WT EGFR tumors were analyzed. PD-1/PD-L1 antibody was associated with significantly longer OS and PFS than chemotherapy (OS: HR 0.67, 95% CrI 0.60–0.75; PFS: HR 0.83, 95% CrI 0.73–0.95) and TKI (OS: HR 0.59, 95% CrI 0.50–0.70; PFS: HR 0.75, 95% CrI 0.66–0.84) , while chemotherapy was associated with significantly longer OS (HR 0.88, 95% CrI 0.77–0.99) and PFS (HR 0.75, 95% CrI 0.66–0.84) than TKI.
Conclusions: For advanced NSCLC patients with WT-EGFR tumors in second- or third-line therapy, PD-1/PD-L1 antibody appeared to be the most efficacious treatment, which was followed by chemotherapy. EGFR-TKI was worse than chemotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.